Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of individuals receiving an autologous hematopoietic stem cell transplant (HCT) for multiple myeloma.

Key facts

Study ID

NCT02420223

Run by

Medical College of Wisconsin

People needed

25

Starts

2015-07-17

Expected to finish

2020-02-01

Last updated by the study team

2021-06-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with multiple myeloma receiving an autologous HCT are eligible when the following criteria are met:
• 18-75 years of age
• ≤ 1 year since initiation of systemic anti-myeloma therapy
• Patient is scheduled for autologous hematopoietic stem cell transplant as the upfront therapy for their multiple myeloma
• Karnofsky Performance Status of ≥90 %; patients eligible for HCT are eligible for the study
• All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.

You may not qualify if…

• Prior autologous HCT
• Non secretory multiple myeloma
• Concurrent beta-blocker therapy at or within 3 weeks of study entry.
• Previous intolerance to beta-blocker therapy
• Any medical contraindications to beta-blocker therapy including, but not limited to, symptomatic hypotension; drug hypersensitivity; sinus bradycardia, sick sinus syndrome, or 2nd or 3rd degree atrioventricular block without a pacemaker; uncompensated heart failure; or uncontrolled asthma
• Active, untreated depression screened for by the HCT physician (Patients who screen positive will be offered a referral to the Medical College of Wisconsin Psycho-Oncology program for further evaluation and treatment)
• Concurrent use of medications as specified in the protocol throughout the study or within one week of study entry.
• Pregnant or lactating women

Where it is running

• Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.